What We Do

Finance

Capital Raising, M&A, Buyouts, IPOs, Financial Structuring:
Breslin has a successful investment, advisory and transaction history with over 80 transactions, predominantly in Biotech and Pharma markets.

Secondary Transactions:
The secondary market broadens the opportunity set for private equity investors, corporates, and privates by providing liquidity and by offering a tool to rebalance and diversify portfolios. 
In 2004, BRESLIN pioneered the execution of private equity secondary transactions in Europe and has since then handled the successful secondary exits of a number of portfolios for BAYER Pharma, followed by many more for industrial, financial and private investors with a volume of over $800m. 

Corporate Development

New Company Formation and Spin-Offs:
Spin-offs are an apt strategy for the formation of new companies to introduce their innovative technologies and products to industrial markets.
With its strong investment background, BRESLIN possesses the necessary know-how in offering guidance to academic and corporate spin-offs. Various spin-offs in Europe have been initiated and managed by BRESLIN.

Business Development:
Based on long-standing expertise and an extensive network within the Biotech and Pharma industries, BRESLIN provides valuable opportunities to its clients for business development, cooperation, in and out licensing, and assistance in strategic or operational processes.

Investment Activities

With its specialized investment firm based in Zurich, Switzerland, BRESLIN has so far provided venture capital to well-known biopharmaceutical companies in Europe, namely Actelion, 4SC, and GPC. We are currently focusing on seed and early stage investments as well as on academic and industrial spin-offs.

Exited Portfolio Companies:

  • Actelion, Switzerland
  • Anawa Laboratories, Switzerland
  • Cardion, Germany
  • Develogen, Germany
  • Glycart, Switzerland
  • GPC Biotech, Germany
  • Igeneon, Austria
  • Switch Biotech, Germany

Current Porfolio:

  • Amypopharma, Italy
  • CoBaLT GmbH, Germany
  • Memo Therapeutics, Switzerland
  • Qithera GmbH, Germany

Switzerland

Breslin AG and Breslin Biotech AG
Gubelstrasse 19
8050 Zürich
Switzerland
+ 41 79 287 7120
info@breslin.ch

Germany

Breslin AG and Breslin Biotech AG
Fichardstrasse 38
60322 Frankfurt am Main
Germany
+ 49 69 91509682 • + 41 79 2877120
breslin@bluewin.ch